NCT05714839 2026-01-23
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
Clinical Trials
11 trialsNCT02343042 2025-12-22
STOMP
Karyopharm Therapeutics Inc
Phase 1/2 Recruiting
NCT07217119 2025-10-15
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07217184 2025-10-15
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07150091 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07150104 2025-09-02
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT07084896 2025-07-25
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03544281 2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2 Completed
NCT06655818 2025-03-03
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Terminated
NCT03848845 2024-04-09
DREAMM 4
GlaxoSmithKline
Phase 1/2 Completed
NCT06160609 2024-03-12
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
GlaxoSmithKline
Phase 1/2 Terminated